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Abstract
African Americans have the highest rate of mortality due to coronary heart disease (CHD). Although multiple loci have been
identified influencing CHD risk in European-Americans using a genome-wide association (GWAS) approach, no GWAS of
incident CHD has been reported for African Americans. We performed a GWAS for incident CHD events collected during 19
years of follow-up in 2,905 African Americans from the Atherosclerosis Risk in Communities (ARIC) study. We identified a
genome-wide significant SNP (rs1859023, MAF=31%) located at 7q21 near the PFTK1 gene (HR=0.57, 95% CI 0.46 to 0.69,
p=1.86610
208), which replicated in an independent sample of over 8,000 African American women from the Women’s
Health Initiative (WHI) (HR=0.81, 95% CI 0.70 to 0.93, p=0.005). PFTK1 encodes a serine/threonine-protein kinase, PFTAIRE-
1, that acts as a cyclin-dependent kinase regulating cell cycle progression and cell proliferation. This is the first finding of
incident CHD locus identified by GWAS in African Americans.
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Introduction
Coronary heart disease (CHD) is the leading cause of death
worldwide [1]. In the United States, African Americans are the
most vulnerable population with regard to CHD risk factors and
mortality. A recent American Heart Association report showed
that African Americans are twice as likely to die from a heart-
related disease compared to other ethnicities [2]. The presence of
multiple CHD risk factors is 50% more likely in African
Americans than in the population of European ancestry.
Hypertension and diabetes are more prevalent and the highest
rate of obesity is found in African American women [2]. The
factors underlying these disparities are not well understood.
Socioeconomic status and health care accessibility play an
important role [3]. However, genetic factors are known to
influence the risk of CHD [4] and population differences in the
frequency and effects of these genetic factors also likely have a role.
Progress in the discovery of susceptibility genes for multiple
chronic diseases and their risk factors has been made possible in
recent years through genome-wide association studies (GWAS);
African Americans were noticeably absent from most of these
studies. GWAS have the advantage of discovering new genetic
variants underlying a disease without a priori knowledge of gene
location or function. More than 20 variants for CHD have been
discovered in samples of European-descent so far [5–11].
In this study, we took advantage of rich longitudinal data on
CHD incident events in the Atherosclerosis Risk in Communities
(ARIC) study and performed a GWAS of incident CHD events in
African Americans. Results that reached pre-specified genome-
wide significance were investigated in African Americans from the
Women’s Health Initiative (WHI) [12].
Results/Discussion
Genome-wide association analysis for incident CHD was
carried out in African Americans from the ARIC study. After 19
years of follow-up, 362 individuals developed CHD and 2,543
individuals were free of CHD. Descriptive statistics for multiple
cardiovascular disease risk factors at the baseline examination are
provided in Table 1. Three loci reached the pre-specified genome-
wide significance threshold (p,5610
28) (Table 2) and were
considered for replication in a sample of African American women
from WHI. Results are shown in Table 2. For all variants, the
direction of effect was consistent in both studies, but only the
variant rs1859023 reached statistical significance in WHI (Table 2).
The rs1859023 minor allele A (frequency=0.31) had a protective
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to 0.69, p=1.86610
208) in ARIC and 0.81 (95% CI 0.70 to 0.93,
p=0.005) in WHI. After adjustment for CHD risk factors
(smoking, diabetes, LDL, BMI and hypertension), the result was
only slightly less significant (HR=0.59, 95% CI 0.48 to 0.73,
p=8.536102
07 in the ARIC study). After exclusions of coronary
revascularization procedures from the ARIC case definition, the
association became stronger (HR 0.53, 95% CI 0.43 to 0.65,
p=2.95610
209), possibly due to a more homogenous definition of
CHD. The pooled hazard ratio of incident CHD for combined
ARIC and WHI data was 0.72 (95% CI 0.64 to 0.81,
p=1.29610
208).
rs1859023 was not significantly associated with any of the
traditional CHD risk factors at the baseline ARIC examination
(LDL, HDL, SBP, DBP and BMI, data not shown). However,
average thickness of the carotid artery, a common measure of
subclinical atherosclerosis, was significantly different among
rs1859023 genotypes (mean difference in carotid artery thickness
per copy of the minor allele b=20.0168, SE=0.0047,
p=3.39610
204) which suggest a role for this variant in the
atherosclerotic process. When including carotid artery wall
thickness as a covariate in the analysis of incident CHD attenuated
but did not abolish the association with rs1859023 (HR=0.59,
95% CI 0.48 to 0.73, p=1.58610
206). We attepted to replicate
this observation by testing the assocation of rs1859023 and right
coronary fatty streak area (% of intimal surface area) in the PDAY
study consisting of 1,452 African Americans and 1,342 European
Americans but the results did not reach statistical significance
using a one-sided test. In the ARIC European Americans,
rs1859023 was not significantly associated with incident CHD.
The smallest p-value in the region surrounding rs1859023
(650 kb) was at rs17869240 (p=0.01, MAF=0.07).
rs1859023 is located in an intergenic region in proximity to the
PFTK1, CLDN12 and GTPBP10 genes (Figure 1). PFTK1, also
known as CDK14, encodes a serine/threonine-protein kinase
PFTAIRE-1 that acts as a cyclin-dependent kinase regulating cell
cycle progression and cell proliferation [13]. It is highly expressed
in heart tissue [14]. In the ARIC study, rs1859023 is in loose
linkage disequilibrium (LD) with other SNPs in the region
(r
2,=0.4). In the Yoruba HapMap data, there are only 3 SNPs
with LD greater than r
2=0.8, all located within a very short
distance of rs1859023 (Figure 1) which implies that the tagging
region of rs1859023 is very narrow in African-derived populations.
Given the location of the rs1859023 59 to the PFTK1 gene, these
data imply that rs1859023 may affect gene expression. To test this
hypothesis, we undertook expression QTL analyses using the
resources provided at the SCAN – SNP and CNV Annotation
Database (http://www.scandb.org/newinterface/about.html) [15].
rs1859023 predicts the expression of 6 genes with p-values less than
10
24 (Table 3). Interestingly, the evidence of rs1859023 predicting
the gene expression is found only in the Yoruba population.
A variant close to PFTK1, rs10499903, located ,60 kb from
rs1859023 was associated with ankle brachial index (ABI) in
European Americans from the Framingham Heart Study (FHS)
[16]. Given the different ethnic backgrounds of the two studies,
and expected difference of LD patterns within the region between
two samples, the Framingham result strengthens our finding and
further suggests a role for the PFTK1 gene region in the
atherosclerotic process.
Some of European-discovered CHD genes have been reported
to also influence CHD in African Americans [17]. However, this is
the first reported GWAS finding of a CHD risk locus in African
Table 1. Baseline characteristics of the ARIC sample.
Characteristic Incident CHD Free of CHD p
N 362 2,543
Age, years 54.98 (5.69) 52.91 (5.72) ,0.0001
Women, % 51.66 65.24 ,0.0001
Hypertension, % 1 71.19 51.88 ,0.0001
Diabetes, % 2 31.55 16.11 ,0.0001
Current smoker, % 39.89 27.15 ,0.0001
Total cholesterol, mg/dL 227.44 (49.62) 213.73 (44.27) ,0.0001
HDL cholesterol, mg/dL 48.32 (13.52) 56.32 (17.56) ,0.0001
LDL cholesterol, mg/dL 152.70 (45.97) 135.89 (42.53) ,0.0001
Triglyceride, mg/dL 134.36 (78.32) 110.89 (82.02) ,0.0001
BMI, kg/m2 30.01 (5.81) 29.59 (6.05) NS
Average follow-up time (mean and range), years 9.86 (0.01–18.77) 16.17 (0.11–19.08)
Age at incident CHD, years 65.35 (7.35)
doi:10.1371/journal.pgen.1002199.t001
Author Summary
In the United States, African Americans are at high risk for
coronary heart disease (CHD). Although environmental
and social factors have a role, genetic factors also
contribute to CHD risk and mortality. Research to identify
genetic factors for CHD susceptibility has been carried out
mostly in Europeans and European Americans and little
has been done in African Americans. Genome wide
association studies (GWAS) provide a means to identify
susceptibility loci without any a priori assumptions about
the functional importance of a gene. In this study, we used
GWAS to identify a novel genomic region associated with
incident CHD events in African Americans from the ARIC
study and replicated this finding in a large sample of
African American women. This region contains several
genes, including PFTK1, that regulate cell cycle progression
and cell proliferation. This is the first report of a
susceptibility locus for incident CHD identified by GWAS
in African Americans.
Incident CHD GWAS in African Americans
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GWAS publications in European-Americans (i.e. often exceeding
100,000 individuals (e.g. [18]), we have combined all of the
available well-powered incident CHD data in African Americans
with genotype data and are able to present results based on
133,415 person-years of follow-up. In addition, supporting
evidence is provided by the association with subclinical athero-
sclerosis and expression QTL analyses. In conclusion, we have
identified a region near the PFTK1 gene as being associated with
incident CHD and subclinical atherosclerosis in African Ameri-
cans. Further studies are needed to examine the cellular or
metabolic mechanisms underlying this association, and large
population-based studies of minority populations are necessary to
more fully understand the impact of genetic factors on multiple
phenotypes in those that bear a disproportionate burden of
disease.
Materials and Methods
The ARIC (Atherosclerosis Risk in Communities) study is a
population-based prospective cohort study of cardiovascular
disease and its risk factors [19]. ARIC includes 15,792 persons
aged 45–64 years at baseline (1987–89), randomly chosen from
four US communities. Of these individuals, 4,266 are self-reported
African Americans. Cohort members completed four clinic
examinations, conducted approximately three years apart between
1987 and 1998, and followed with annual phone interviews since
1987.
Incident CHD in ARIC was ascertained by contacting
participants annually, identifying hospitalizations and deaths
during the prior year, and by surveying discharge lists from local
hospitals and death certificates from state vital statistics offices for
potential cardiovascular events [19]. A CHD event was defined as
a validated definite or probable hospitalized MI, a definite CHD
death, an unrecognized MI defined by ARIC ECG readings, or
coronary revascularization. Participants were excluded from
analyses if they had a positive or unknown history of prevalent
stroke, transient ischemic attack/stroke symptoms, or CHD at the
initial visit and/or being of non–African American ethnicity. Real-
time, B-mode ultrasound was used to evaluate the carotid arterial
intima-media wall thickness as an indicator of atherosclerosis in
the ARIC study and the detailed description of its measurement is
described elsewhere [17].
Genotyping was done in 15,020 ARIC participants using the
Affymetrix Genome-Wide Human SNP Array 6.0. A total of 3,182
individuals remained after excluding individuals of non African
American ethnicity, subjects who did not consent DNA use,
unintentional duplicates with higher missing genotype rates,
suspected mixed/contaminated samples, scans from one problem
plate, samples with a mismatch between called and phenotypic
sex, samples with genotype mismatch with 39 previously
genotyped SNPs, suspected first-degree relative of an included
individual, and genetic outliers based on average IBS statistics and
principal components analysis using EIGENSTRAT. SNPs were
excluded due to having no chromosome location, being mono-
morphic, having a call rate ,95% and HWE-p,10
25. In this
analysis, we considered only variants with a MAF greater than
10%.
Cox proportional hazards models with adjustment for age,
gender and the first three principal components derived from
EIGENSTRAT were used to estimate CHD hazard rate ratios
(HRs) over a 19-year period (362 cases) under an additive genetic
model. These analyses were done using PLINK and an R
application for survival regression analyses. We define as
‘‘genome-wide significant’’ all associations with p,5610
28.W e
define replication to be a significant (p,0.05) and directionally
consistent association in an independent sample.
The WHI has two major components: (1) a clinical trial that
enrolled and randomized 68,132 women ages 50–79 into at least
one of three clinical trials; and (2) an observational study that
enrolled 93,676 women ages 50–79 into a parallel prospective
cohort study [12]. WHI participants were recruited from 1993–
1998 at 40 clinical centers across the U.S. During follow-up,
incident CHD events were adjudicated locally and centrally from
medical records including hospital discharge summaries, ICD-9
codes, diagnostic, laboratory, surgical, and pathology reports by
trained physicians blinded to randomized intervention and
exposure status [20]. In the WHI replication sample, CHD was
defined as MI, coronary revascularization, hospitalized angina, or
CHD death. Definite and probable nonfatal MI required
overnight hospitalization and was defined according to an
algorithm based on standardized criteria using cardiac pain,
cardiac enzymes and troponin levels, and ECG findings. CHD
death was defined as death consistent with underlying cause of
CHD plus one or more of the following: hospitalization for MI
within 28 days prior to death, previous angina or myocardial
infarction, death due to a procedure related to CHD, or a death
certificate consistent with underlying cause of atherosclerotic
CHD.
Of a total of 26,045 (17%) women from minority groups, 8,515
self identified African American women who had consented to
genetic research were eligible for the WHI GWAS project.
Genotyping was performed on the Affymetrix 6.0 array. After
excluding samples due to genotyping failure, cryptic relatedness,
and discrepancy between genetic ancestry and self-reported race,
there were 8,421 WHI African Americans. Participants were
further excluded from analyses if they had a positive or unknown
history of prevalent stroke, transient ischemic attack/stroke
symptoms, or CHD at the initial visit. A total of 862 incident
first CHD events occurred among 8,155 eligible African American
Table 2. Association results for genome-wide significant variants associated with incident CHD in ARIC African Americans and
replication results in WHI.
ARIC Replication – WHI
SNP chr MAF gene HR 95% CI p HR 95% CI p
rs2283524 16 0.11 G HS3ST2 1.89 1.55, 2.31 4.61E-10 1.08 0.85, 1.37 0.53
rs574007 7 0.27 G AC017060.1 1.61 1.37, 1.90 1.01E-08 1.02 0.84, 1.20 0.96
rs1859023 7 0.31 A PFTK1 0.57 0.46, 0.69 1.86E-08 0.81 0.70, 0.93 0.005
doi:10.1371/journal.pgen.1002199.t002
Incident CHD GWAS in African Americans
PLoS Genetics | www.plosgenetics.org 3 August 2011 | Volume 7 | Issue 8 | e1002199women without baseline CHD (Table 4). The mean age at study
entry was 61.6+/27.0 years (range 50–79). The mean baseline age
of the cases was 64.2+/27.2, and the mean baseline age of the
non-cases was 61.3+/26.9. The mean time to CHD event was
5.29+/23.19 years. The mean age at CHD event was 69.5+/
27.5 years.
This study was approved by the participating institutional IRBs,
and all ARIC and WHI participants provided written informed
consent, involving the sharing of data with the scientific
community.
The Pathobiolobical Determinants of Atherosclerosis in Youth
(PDAY) study is composed of subjects who were 15 to 34 years of
Figure 1. Regional plot (ARIC) of rs1859023 association with incident CHD and LD in the region arround rs1859023 (YRI) [22,23].
doi:10.1371/journal.pgen.1002199.g001
Incident CHD GWAS in African Americans
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homicides or suicides). The purpose of PDAY was to evaluate
early development of atherosclerosis [21]. For this replication
analysis, we genotyped rs1859023 in 2,794 individuals from PDAY
- 1,452 African Americans and 1,342 European Americans and
tested the association with fatty streak area in the right coronary
artery.
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Table 4. Baseline characteristics of the WHI sample.
Characteristic Incident CHD Free of CHD p
N 862 7.293
Age, years 64.2 (7.2) 61.3 (6.9) ,0.0001
Women, % 100 100 NS
Hysterectomy, % 61.4 55.5 0.0015
WHI Hormone Trial
participant, %
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